LanZhou Foci Pharmaceutical Co.,Ltd.
Simbolis: 002644.SZ
SHZ
7.78
CNYRinkos kaina šiandien
68.3675
P/E santykis
-2.3694
PEG koeficientas
3.97B
MRK kapitalizacija
- 0.01%
DIV pajamingumas
LanZhou Foci Pharmaceutical Co.,Ltd. (002644-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1413.19 | 406 | 398.5 | 374.9 | |||||||||||||||||
balance-sheet.row.short-term-investments | -70.42 | -15.8 | 2 | -10.4 | |||||||||||||||||
balance-sheet.row.net-receivables | 2046.86 | 441.8 | 526.5 | 390.8 | |||||||||||||||||
balance-sheet.row.inventory | 1526.12 | 369.7 | 350.4 | 258.8 | |||||||||||||||||
balance-sheet.row.other-current-assets | 74.04 | 21.3 | 15.7 | 10 | |||||||||||||||||
balance-sheet.row.total-current-assets | 5060.22 | 1238.9 | 1291.1 | 1034.6 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 4211.94 | 1061.8 | 1066.8 | 1091.6 | |||||||||||||||||
balance-sheet.row.goodwill | 26.96 | 9 | 4.5 | 4.5 | |||||||||||||||||
balance-sheet.row.intangible-assets | 320.66 | 79.6 | 76.8 | 72 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 347.63 | 88.6 | 81.3 | 76.4 | |||||||||||||||||
balance-sheet.row.long-term-investments | 335.99 | 79.9 | 66.7 | 82.1 | |||||||||||||||||
balance-sheet.row.tax-assets | 205.41 | 53.6 | 52.4 | 51.1 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 54.24 | 5.3 | 28.4 | 16.2 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 5155.21 | 1289.2 | 1295.5 | 1317.5 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 10215.43 | 2528.1 | 2586.6 | 2352.1 | |||||||||||||||||
balance-sheet.row.account-payables | 1338.65 | 310.4 | 311 | 214.3 | |||||||||||||||||
balance-sheet.row.short-term-debt | 98.74 | 24.7 | 13.8 | 14.7 | |||||||||||||||||
balance-sheet.row.tax-payables | 130.95 | 35.1 | 69.4 | 47.6 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 14.55 | 1.3 | 0.5 | 0.8 | |||||||||||||||||
Deferred Revenue Non Current | 1056.95 | 261 | 278.2 | 295 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 10.03 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 19.4 | 5.8 | 110.9 | 4.5 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1174.53 | 292 | 322.1 | 349.8 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 3.23 | 1.3 | 0.5 | 0.8 | |||||||||||||||||
balance-sheet.row.total-liab | 3126.08 | 759.7 | 852.6 | 724.6 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 2042.63 | 510.7 | 510.7 | 510.7 | |||||||||||||||||
balance-sheet.row.retained-earnings | 3119.21 | 776.2 | 746.9 | 654.5 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1237.35 | 158.4 | 152 | 143.6 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 605.87 | 300.1 | 305.8 | 305.8 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 7005.06 | 1745.4 | 1715.4 | 1614.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 10215.43 | 2528.1 | 2586.6 | 2352.1 | |||||||||||||||||
balance-sheet.row.minority-interest | 84.28 | 23.1 | 18.6 | 12.9 | |||||||||||||||||
balance-sheet.row.total-equity | 7089.35 | 1768.4 | 1734 | 1627.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 10215.43 | - | - | - | |||||||||||||||||
Total Investments | 265.57 | 64.1 | 68.7 | 71.7 | |||||||||||||||||
balance-sheet.row.total-debt | 113.29 | 26 | 14.4 | 15.5 | |||||||||||||||||
balance-sheet.row.net-debt | -1299.9 | -380 | -382.1 | -359.4 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 58.12 | 68.1 | 105.9 | 93.5 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 3.63 | 52.5 | 49.5 | 48.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0.2 | 1 | 0.2 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -0.2 | -1 | -0.2 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 66.85 | -82.3 | -112.2 | -117 | |||||||||||||||||
cash-flows.row.account-receivables | 59.5 | 59.5 | -210.1 | -66.8 | |||||||||||||||||
cash-flows.row.inventory | -7.3 | -7.3 | -91.7 | -0.8 | |||||||||||||||||
cash-flows.row.account-payables | 0 | -134.7 | 188.6 | -49.5 | |||||||||||||||||
cash-flows.row.other-working-capital | 14.64 | 0.2 | 1 | 0.2 | |||||||||||||||||
cash-flows.row.other-non-cash-items | -71.03 | 27.4 | 29.1 | -13.2 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 57.56 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -8.98 | -22.5 | -41.5 | -32.8 | |||||||||||||||||
cash-flows.row.acquisitions-net | -15.45 | -15.5 | 3.9 | 74.1 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 8.95 | -6 | -2.1 | -3.9 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 7.98 | 8 | -3.9 | 38.1 | |||||||||||||||||
cash-flows.row.other-investing-activites | -15.17 | 1.8 | 0.8 | -32.8 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -22.66 | -34.2 | -42.8 | 42.6 | |||||||||||||||||
cash-flows.row.debt-repayment | -22.59 | -21.5 | -14.2 | -35.3 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | -0.5 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | -1.65 | -27.9 | -5.1 | -61.4 | |||||||||||||||||
cash-flows.row.other-financing-activites | -11.1 | -1.3 | 3.9 | 3.3 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -50.87 | -25 | -15.5 | -93.4 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 25.84 | 0.7 | 0.7 | -0.2 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 9.86 | 7.2 | 14.8 | -39.1 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1376.43 | 396.3 | 387.7 | 372.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1366.56 | 389.1 | 372.9 | 412 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 57.56 | 65.7 | 72.4 | 11.9 | |||||||||||||||||
cash-flows.row.capital-expenditure | -8.98 | -22.5 | -41.5 | -32.8 | |||||||||||||||||
cash-flows.row.free-cash-flow | 48.58 | 43.2 | 30.9 | -21 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1130.07 | 1163.1 | 1019.2 | 817.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 765.41 | 801.8 | 733 | 594.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 364.66 | 361.3 | 286.2 | 223.1 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 31.51 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 17.15 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 154.39 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | -2.01 | -1.6 | -9.7 | 24.4 | |||||||||||||||||
income-statement-row.row.operating-expenses | 262.09 | 262 | 129.4 | 134.6 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 1027.5 | 1063.8 | 862.3 | 729 | |||||||||||||||||
income-statement-row.row.interest-income | 2.93 | 5.4 | 7.5 | 10.2 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.2 | 0.7 | 0.9 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 154.39 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -2.01 | -1.6 | -12.4 | -1.5 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | -2.01 | -1.6 | -9.7 | 24.4 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -2.01 | -1.6 | -12.4 | -1.5 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.2 | 0.7 | 0.9 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 40.06 | 52.5 | 62.2 | 32.2 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 112.68 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 72.62 | 83.3 | 139.4 | 112.4 | |||||||||||||||||
income-statement-row.row.income-before-tax | 70.6 | 81.6 | 127 | 110.8 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 11.28 | 13.5 | 21.1 | 17.3 | |||||||||||||||||
income-statement-row.row.net-income | 58.12 | 67.2 | 108.7 | 93.3 |
Dažnai užduodami klausimai
Kas yra LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) bendras turtas?
LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) bendras turtas yra 2528102214.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 576952643.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.323.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.095.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.051.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.064.
Kas yra LanZhou Foci Pharmaceutical Co.,Ltd. (002644.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 67189706.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 26031519.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 261964435.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 365338610.000.